Future Directions in Treatment of ST Segment Elevation Myocardial Infarction

Joint Coronary Revascularization
Busan, Korea December 13, 2014

Thach Nguyen MD FACC FSCAI
Director of Cardiology
St Mary Medical Center, Hobart IN
When you hear the positive results of a new drug on prevention of DVT (deep vein thrombosis) for patient undergoing knee surgery, what do you expect to hear:

- 2 years later
- 4 years later
- 6 years later?
1. Prevention of DVT for knee and hip procedure
2. Prevention and treatment of pulmonary embolism
3. Treatment of Unstable angina
4. Use in PCI
5. Treatment of ACS
6. Treatment of STEMI
Why this sequence?
Demand of the markets
a. When benefits outweigh the risks

or b. when the rate of complications is down
PCI of LM versus CABG
a. When benefits outweigh the risks

or  b. when the rate of complications is down
A. Four Metrics measuring the success of a hospital
a. Clinical outcome
b. Patient satisfaction
c. Financial health of the hospital
d. Operational efficiency
B. When Will A New Disruptive Technology Take Off?
1. Cheaper,
2. Easy to use
3. Comparable efficacy
A *disruptive technology* is a new one that emerges and displaces the old established technology and shakes up the industry.
1. P2 y12 inhibitors for PCI
• Substudy of 7544 STEMI patients with planned PCI from the PLATO Trial

• Ticagrelor was superior to clopidogrel
  – Primary endpoint (composite of MI, stroke, CV death)
  – Secondary endpoints (MI alone, total mortality, stent thrombosis)

• Major bleeding not increased

• Circulation. 2010;122:2131-2141
Pre-hospital ticagrelor?

- ATLANTIC trial (N Engl J Med 2014;371:1016-27) 1862 STEMI patients with ambulance vs cath lab ticagrelor
- Ambulance group treated 31 minutes earlier
- No difference in pre-PCI coronary reperfusion (by ECG or TIMI flow)
- Stent thrombosis reduced
- No increased risk of bleeding
A. Number of patients with ACS is much higher compared with STEMI patients. Need higher market share
B. Why do we need to have upstream treatment? First contact with medical personnel and will continue to be given
2. Anticoagulant for PCI
Bivalirudin: HORIZONS-AMI

Patients With STEMI Undergoing PCI

- All-Cause Mortality: 7.70% vs. 5.90% (P = .03)
- Major Bleeding: 10.50% vs. 6.90% (P = .001)
- TVR: 14.20% vs. 12.10% (P = .06)
- Stent Thrombosis: 5.10% vs. 4.50% (P = .49)

HEAT PPCI: *Heparin vs Bivalirudin in Primary PCI*

- Single center randomized controlled trial (Liverpool, UK)
- Feb 2012 – Nov 2013
- STEMI patients
  - **Heparin 70 U/kg**
    - Bivalirudin 0.75 mg/kg bolus, 1.75 mg/kg/hr infusion
    - Selective (bailout) abciximab
- Primary outcome at 28 days
  - MACE
  - Major bleeding
- 1917 pts screened, 1829 enrolled
HEAT PPCI: Procedural characteristics

- Radial access 80%
- P2Y12
  - Clopidogrel 11%
  - Prasugrel 27%
  - Ticagrelor 62%
- Abxicimab 14%
- PCI performed 82%
Timing of First MACE Event

Event curve shows first event experienced

<table>
<thead>
<tr>
<th>No. at risk</th>
<th>Days</th>
<th>Heparin</th>
<th>Bivalirudin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>907</td>
<td>905</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>871</td>
<td>853</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>866</td>
<td>844</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>862</td>
<td>835</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>857</td>
<td>830</td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>856</td>
<td>828</td>
</tr>
<tr>
<td></td>
<td>30</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## HEAT PPCI: Results

<table>
<thead>
<tr>
<th>(%)</th>
<th>Bivalirudin</th>
<th>Heparin</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>MACE</td>
<td>8.7</td>
<td>5.7</td>
<td>0.01</td>
</tr>
<tr>
<td>Reinfarction</td>
<td>2.7</td>
<td>0.9</td>
<td></td>
</tr>
<tr>
<td>TLR</td>
<td>2.7</td>
<td>0.7</td>
<td></td>
</tr>
<tr>
<td>Stent Thrombosis</td>
<td>3.4</td>
<td>0.9</td>
<td>0.001</td>
</tr>
<tr>
<td>Major bleed</td>
<td>3.5</td>
<td>3.1</td>
<td>0.59</td>
</tr>
</tbody>
</table>
BRIGHT Trial

*Bivalirudin vs Heparin and Heparin + Tirofiban in Primary PCI*

- Multicenter randomized controlled trial (China)
- 2194 AMI patients
  - Bivalirudin 0.75 mg/kg bolus, 1.75 mg/kg/hr then 0.2 mg/kg/hr (234 min)
  - Heparin 100 U/kg
    - Heparin 60 U/kg + Tirofiban 10µg/kg bolus, 0.15µg/kg/min for 18-36 hrs
- Primary endpoint: NACE at 30 days
- Secondary endpoints
  - NACE at 1 year
  - MACCE at 30 days, 1 year
  - Bleeding at 30 days, 1 year

Han *TCT 2014*
BRIGHT: *Procedural characteristics*

- STEMI 88%, NSTEMI 12%
- Radial access 78%
- Door to device time 66-70 min
- Clopidogrel 100%
- PCI performed 98%
- Stent 96%

Han *TCT 2014*
BRIGHT

Primary and principal secondary endpoints at 30 days

- Biv vs. UFH, p=0.009
  Relative risk 0.67 (0.50-0.90), NNT=23.1
- Biv vs. H+T, p < 0.001
  Relative risk 0.52 (0.39-0.69), NNT=12.3
- UFH vs. H+T, p=0.04
  Relative risk 0.78 (0.61-0.99), NNT=26.2
BRIGHT

Stent thrombosis at 30 days – STEMI only

Han TCT 2014
BRIGHT
Major ischemic events at 1 year

Han TCT 2014
# BRIGHT

**Bleeding events at 30 days**

<table>
<thead>
<tr>
<th>Event</th>
<th>Bivalirudin (N = 735)</th>
<th>Heparin (N = 729)</th>
<th>Heparin + Tirofiban (N = 730)</th>
<th>P value (3-way)</th>
<th>P value (B vs H)</th>
<th>P value (B vs H+T)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any bleeding</td>
<td>30 (4.1)</td>
<td>55 (7.5)</td>
<td>90 (12.3)</td>
<td>&lt;0.001</td>
<td>0.005</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BARC 1 (%)</td>
<td>21 (2.9)</td>
<td>29 (4.0)</td>
<td>53 (7.3)</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BARC 2 (%)</td>
<td>5 (0.7)</td>
<td>15 (2.1)</td>
<td>22 (3.0)</td>
<td>0.005</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BARC 3a (%)</td>
<td>4 (0.5)</td>
<td>7 (1.0)</td>
<td>6 (0.8)</td>
<td>0.59</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BARC 3b (%)</td>
<td>0 (0)</td>
<td>4 (0.5)</td>
<td>8 (1.1)</td>
<td>0.013</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BARC 5 (%)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (0.1)</td>
<td>0.67</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BARC 2-5 (%)</td>
<td>9 (1.2)</td>
<td>26 (3.6)</td>
<td>37 (5.1)</td>
<td>&lt;0.001</td>
<td>0.003</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Major (BARC 3-5) (%)</td>
<td>4 (0.5)</td>
<td>11 (1.5)</td>
<td>15 (2.1)</td>
<td>0.04</td>
<td>0.07</td>
<td>0.01</td>
</tr>
</tbody>
</table>

Han *TCT 2014*
Putting HEAT and BRIGHT together…

- The mortality benefit for bivalirudin in primary PCI seen in HORIZONS-AMI was not confirmed in either HEAT or BRIGHT
- No MACE advantage for bivalirudin over heparin monotherapy
- Bivalirudin usage is associated with less bleeding than heparin 100 U/kg (BRIGHT) but is equivalent to heparin 70 U/kg (HEAT)
- Compared to heparin, bivalirudin usage results in increased rates of early stent thrombosis. This may be eliminated by continuing the bivalirudin for 4 hours post-PCI.
When Will A New Disruptive Technology Take Off?
1. Cheaper,
2. Easy to use
3. Comparable efficacy
3. Anticoagulant after PCI
PLATO, TRITON-TIMI 38, and CURE
Residual Risk

Primary end point:
Death from CV causes, nonfatal MI, nonfatal stroke

<table>
<thead>
<tr>
<th></th>
<th>PLATO\textsuperscript{a}</th>
<th>TRITON-TIMI 38\textsuperscript{b}</th>
<th>CURE\textsuperscript{c}</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ticagrelor</td>
<td>9.8</td>
<td>9.9</td>
<td>9.3</td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>11.7</td>
<td>12.1</td>
<td>11.4</td>
</tr>
<tr>
<td>Prasugrel</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

HR = 16%          
HR = 19%          
HR = 20%

ATLAS ACS 2—TIMI 51

Mortality Benefit

P values represent mITT values.

Rivaroxaban: ATLAS ACS 2-TIMI 51: Study Design

Patients Recently Diagnosed With ACS
N = 15,526
Randomly assigned within 7 days after admission; median 4.7 days

Aspirin Dosage:
75-100 mg/d

Aspirin Only
1:1:1

Placebo
Rivaroxaban
2.5 mg × 2
Rivaroxaban
5 mg × 2

Placebo

Aspirin + Thienopyridine
1:1:1

Rivaroxaban
2.5 mg × 2
Rivaroxaban
5 mg × 2

Treatment: Maximum, 31 months; mean, 13.1 months

Primary efficacy end point: CV death, MI, or stroke
Primary safety end point: TIMI major bleeding (*not associated with CABG*)

ATLAS ACS 2-TIMI 51: Mortality Benefit With Very Low-Dose Rivaroxaban in STEMI Patients

N=7817

All-Cause Death

Death From CV Causes

---

Rivaroxaban 2.5 mg (ITT) 3.0% 4.7%
P = .008

Rivaroxaban 2.5 mg (mITT) 2.5%
P = .007

Placebo (ITT) 4.3%

Placebo (mITT) 4.2%
P = .006

Rivaroxaban 2.5 mg (ITT) 2.5%
P = .006

Rivaroxaban 2.5 mg (mITT) 2.2%

Placebo (ITT) 4.2%

Placebo (mITT) 3.9%

---

Rivaroxaban: PIONEER AF-PCI

Patients With Documented AF Who Undergo PCI
N = 2,100

Rivaroxaban 2.5 mg twice daily
  + low-dose aspirin daily
  + clopidogrel 75 mg/d or prasugrel 10 mg/d or ticagrelor 90 mg tablet twice daily

Followed by rivaroxaban 15 mg
  (or 10 mg in moderate renal impairment)/d
  + low-dose aspirin for 12 months

VKA daily (target INR 2.0 to 3.0) + plus low-dose aspirin
  + clopidogrel 75 mg/d or prasugrel 10 mg/d or ticagrelor 90 mg twice daily

Followed by dose-adjusted VKA daily + low-dose aspirin for 12 months

Rivaroxaban 15 mg
  (or 10 mg in moderate renal impairment)/d + clopidogrel 75 mg/d or prasugrel 10 mg/d or ticagrelor 90 mg twice daily for 12 months

Primary outcome: Clinically significant bleeding at 12 months (composite of TIMI major bleeding, minor bleeding, and bleeding requiring medical attention)
Secondary outcome: Composite of CV death, MI, and stroke

clinicaltrials.gov[^10]
Otamixaban: TAO Study Design

June 4, 2013, update: The study did not meet its primary end point of superiority over current therapy and the investigational program for otamixaban will be discontinued.

Primary efficacy end point: All-cause death or new MI to day 7; safety end point TIMI significant bleeding to day 7
4. Thrombectomy
Manual aspiration thrombectomy is performed to the LAD and diagonal with improved flow

Before thrombectomy

After thrombectomy
TAPAS

- TAPAS trial: Manual aspiration of thrombus prior to balloon/stent (NEJM 2008;358:557-567)
  - Improved myocardial perfusion
  - Reduction of mortality at 1-year followup (Lancet 2008;371:1915-1920)
INFUSE AMI

• INFUSE-AMI (JAMA 2012;307:1817-26)
  - 452 patients at 37 sites with LAD STEMI
  - Evaluating intracoronary abciximab and manual aspiration thrombectomy
  - Primary end point: infarct size at 30 days by cardiac MRI
  - Small benefit for abciximab but not thrombectomy
7244 patients with STEMI PCI
Aspiration thrombectomy + PCI vs PCI alone
No reduction in early or late MACE

Thrombectomy in STEMI PCI

Conclusions

• Simple and safe procedure
• May improve procedural myocardial perfusion
• No early mortality reduction although possible improved mortality at 1 year (seen in TAPAS but not in TASTE)
Could not find the subset of patients who will need manual thrombectomy yet
a. Clinical outcome
b. Patient satisfaction
c. Financial health of the hospital
d. Operational efficiency
5. PCI for non-Infarct Related artery
Post thrombectomy, angioplasty

Stenting of LAD

Post stent
How should the non-infarct vessel be treated?
• 465 STEMI patients with successful infarct artery PCI who also had ≥50% stenosis in at least one other vessel
  - 234 underwent immediate PCI of noninfarct vessels
  - 231 were treated with optimal medical therapy
• Endpoints: Primary: Composite of cardiac death, MI, or refractory angina
• Study was stopped early due to highly significant (P<0.001) difference favoring immediate PCI
# PRAMI
**Prespecified Clinical Outcomes**

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Preventive PCI (N=234)</th>
<th>No Preventive PCI (N=231)</th>
<th>Hazard Ratio (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary outcome</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death from cardiac causes, nonfatal myocardial infarction, or refractory angina†</td>
<td>21</td>
<td>53</td>
<td>0.35 (0.21–0.58)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Death from cardiac causes or nonfatal myocardial infarction†</td>
<td>11</td>
<td>27</td>
<td>0.36 (0.18–0.73)</td>
<td>0.004</td>
</tr>
<tr>
<td>Death from cardiac causes</td>
<td>4</td>
<td>10</td>
<td>0.34 (0.11–1.08)</td>
<td>0.07</td>
</tr>
<tr>
<td>Nonfatal myocardial infarction</td>
<td>7</td>
<td>20</td>
<td>0.32 (0.13–0.75)</td>
<td>0.009</td>
</tr>
<tr>
<td>Refractory angina</td>
<td>12</td>
<td>30</td>
<td>0.35 (0.18–0.69)</td>
<td>0.002</td>
</tr>
<tr>
<td><strong>Secondary outcomes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death from noncardiac causes</td>
<td>8</td>
<td>6</td>
<td>1.10 (0.38–3.18)</td>
<td>0.86</td>
</tr>
<tr>
<td>Repeat revascularization</td>
<td>16</td>
<td>46</td>
<td>0.30 (0.17–0.56)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

* All patients underwent infarct-artery PCI.
† Only the first event per patient is listed.

A. Four Metrics measuring the success of a hospital
a. Clinical outcome
b. Patient satisfaction
c. Financial health of the hospital
d. Operational efficiency
B. When Will A New Disruptive Technology Take Off?
1. Cheaper,
2. Easy to use
3. Comparable efficacy
A disruptive technology is a new one that emerges and displaces the old established technology and shakes up the industry.
a. Heparin > bivalirudin
b. Anticoagulant after AMI.
c. Thrombectomy for special subset of patient
d. Non IRA PCI for special subsets of patients
Thank You